NO2887943T3 - - Google Patents

Info

Publication number
NO2887943T3
NO2887943T3 NO13831626A NO13831626A NO2887943T3 NO 2887943 T3 NO2887943 T3 NO 2887943T3 NO 13831626 A NO13831626 A NO 13831626A NO 13831626 A NO13831626 A NO 13831626A NO 2887943 T3 NO2887943 T3 NO 2887943T3
Authority
NO
Norway
Application number
NO13831626A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2887943(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2887943T3 publication Critical patent/NO2887943T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NO13831626A 2012-05-31 2013-08-23 NO2887943T3 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
NO2887943T3 true NO2887943T3 (no) 2018-05-05

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13831626A NO2887943T3 (no) 2012-05-31 2013-08-23

Country Status (29)

Country Link
US (1) US9675692B2 (no)
EP (1) EP2854849B1 (no)
JP (1) JP6144758B2 (no)
KR (1) KR20150033615A (no)
CN (1) CN104349791A (no)
AR (1) AR092325A1 (no)
AU (1) AU2013267301B2 (no)
BR (1) BR112014028997A2 (no)
CA (1) CA2872275C (no)
CL (1) CL2014003237A1 (no)
CO (1) CO7151478A2 (no)
DK (1) DK2854849T3 (no)
EA (1) EA029779B1 (no)
ES (1) ES2668900T3 (no)
HK (1) HK1207305A1 (no)
IL (1) IL235468A0 (no)
LT (1) LT2854849T (no)
MA (1) MA37645B1 (no)
MX (1) MX357146B (no)
NO (1) NO2887943T3 (no)
NZ (1) NZ702288A (no)
PH (1) PH12014502429A1 (no)
PL (1) PL2854849T3 (no)
PT (1) PT2854849T (no)
SG (1) SG11201407171XA (no)
SI (1) SI2854849T1 (no)
TW (1) TWI609696B (no)
UY (1) UY34842A (no)
WO (1) WO2013181486A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
BR112014007035B1 (pt) 2011-09-23 2021-05-04 Oncomed Pharmaceuticals, Inc anticorpos biespecíficos que se ligam a vegf/dll4, composição farmacêutica e célula procariótica, fúngica ou de levedura que compreende os mesmos, moléculas de polinucleotídeo, vetor, usos terapêuticos e método para a produção de um anticorpo
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
KR20200144120A (ko) * 2018-04-16 2020-12-28 메르크 파텐트 게엠베하 열 안정성을 개선하기 위한 단백질 제제에 대한 첨가제
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
AU2021305093A1 (en) * 2020-07-08 2023-03-09 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-CTLA-4 antibodies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
WO2002030463A2 (en) 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20050118163A1 (en) 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060217311A1 (en) 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
MX2011009306A (es) 2009-03-06 2011-10-13 Genentech Inc Formulacion con anticuerpo.
ES2895226T3 (es) * 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
RU2548772C2 (ru) 2009-11-20 2015-04-20 Биокон Лимитед Составы антитела
MY160628A (en) * 2010-03-02 2017-03-15 Abbvie Inc Therapeutic DLL4 Binding Proteins
MX366337B (es) * 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).

Also Published As

Publication number Publication date
PH12014502429B1 (en) 2015-01-12
HK1207305A1 (en) 2016-01-29
CO7151478A2 (es) 2014-12-29
MX357146B (es) 2018-06-28
MA37645A3 (fr) 2017-07-31
JP6144758B2 (ja) 2017-06-07
MX2014014363A (es) 2015-02-05
US20130323260A1 (en) 2013-12-05
TW201400130A (zh) 2014-01-01
CA2872275A1 (en) 2013-12-05
WO2013181486A1 (en) 2013-12-05
SG11201407171XA (en) 2014-11-27
EA201492186A1 (ru) 2015-08-31
IL235468A0 (en) 2014-12-31
NZ702288A (en) 2016-12-23
BR112014028997A2 (pt) 2017-07-25
CL2014003237A1 (es) 2015-07-10
JP2015520173A (ja) 2015-07-16
US9675692B2 (en) 2017-06-13
CN104349791A (zh) 2015-02-11
AU2013267301A1 (en) 2014-12-18
AU2013267301B2 (en) 2018-02-08
MA37645A2 (fr) 2016-08-31
PT2854849T (pt) 2018-05-09
AR092325A1 (es) 2015-04-15
CA2872275C (en) 2021-05-18
TWI609696B (zh) 2018-01-01
PL2854849T3 (pl) 2018-07-31
PH12014502429A1 (en) 2015-01-12
KR20150033615A (ko) 2015-04-01
DK2854849T3 (en) 2018-04-30
SI2854849T1 (en) 2018-05-31
ES2668900T3 (es) 2018-05-23
EA029779B1 (ru) 2018-05-31
LT2854849T (lt) 2018-05-10
EP2854849B1 (en) 2018-02-28
UY34842A (es) 2013-12-31
EP2854849A1 (en) 2015-04-08
MA37645B1 (fr) 2018-10-31

Similar Documents

Publication Publication Date Title
BR112014017635A2 (no)
BR112014018750A2 (no)
BR112014017614A2 (no)
BR112014017913A2 (no)
BR112014017625A2 (no)
BR112014017659A2 (no)
BR112014017646A2 (no)
BR112014017638A2 (no)
BR112014017607A2 (no)
BR112014020080A2 (no)
BR112014017634A2 (no)
BR112014017644A2 (no)
BR112014017647A2 (no)
BR112014017618A2 (no)
BR112014017630A2 (no)
BR112014017652A2 (no)
BR112014017621A2 (no)
BR112014017622A2 (no)
BR112014017627A2 (no)
BR112014017623A2 (no)
BR112014017641A2 (no)
BR112014017631A2 (no)
BR112014017636A2 (no)
BR112014017667A2 (no)
BR112014017600A2 (no)